Current naming method of therapeutic mAb drugs
•
0 likes•6 views
Palivizumab (brand name Synagis) is a humanized IgG monoclonal antibody (mAb) manufactured by MedImmune with recombinant DNA technology.https://www.creativebiolabs.net/palivizumab-overview.htm
Report
Share
Report
Share
Download to read offline
Recommended
Approved Therapeutic Antibody Drug and Revenue
The document discusses the four major types of monoclonal antibodies (mAbs) that have been developed: murine, chimeric, humanized, and human. It provides examples of marketed mAb drugs for each type and explains that their generic names follow specific suffixes that indicate the antibody's source and structure. The names generally follow the format of prefix–target–source–suffix according to World Health Organization nomenclature guidelines.
Synteny a million year old euphoria of euphorbiaceae
This document presents the results of a study on synteny between the genome of Ricinus communis and the genomes of several other plants, including Populus trichocarpa, Arabidopsis thaliana, Vitis vinifera, Medicago truncatula, Lotus japonicus, Brachypodium distachyon, Sorghum bicolor, Jatropha curcas, and Manihot esculenta. The study found syntenic relationships between the genome of R. communis and the genomes of these other plants, suggesting conserved chromosomal structures over millions of years of evolution within the plant family Euphorbiaceae.
Ma
This document describes the development of several in vivo experimental models for anti-cancer research including: 1) heterotransplant models using human tumor xenografts in mice to preserve the tumor microenvironment; 2) transgenic mouse models that overexpress oncogenes or knockout tumor suppressor genes; and 3) conditional knockout mouse models where genes can be conditionally deleted in specific tissues. Details are provided on generating transgenic mouse lines that overexpress a deleted form of DNMT3B and generating a conditional HuR knockout mouse line using a targeting vector with loxP sites. The goals are to have repeatable, systematic preclinical models to better evaluate drug efficacy.
Antibody Library Screening - Creative Biolabs
Welcome to Creative Biolabs. As a new preparation technology for genetically engineered antibodies, antibody library technology has important theoretical and practical value in the cloning of human antibodies, antibody performance modification, and antibody gene research. Here, we will explore the de novo antibody library screening technologies and the corresponding services.
Genomic approaches to trypanosome resistance
Elucidating changes in gene expression in Tryp susceptible and resistant cattle during progression of tryp infection using Affymetrix gene expression Micro arrays
B cell sorting
The single plasma cell interrogation platform uses single cell-based screening of entire antibody-secreting B cell populations along with next-generation sequencing to retrieve native antibodies with extremely high in vivo specificity and affinity. During the native antibody development, the isolation and separation of single cells are the main technically challenging tasks. The yield and quality or in other words the integrity and purity of the cells as well as the throughput and the sensitivity of single cell isolation methods should be considered.
Non-GMP Antibody Production
flexible, efficient Non-GMP antibody production services to advance the development of increasing number of therapeutic monoclonal antibody candidates, from process development to aseptic filling
https://www.creativebiolabs.net/non-gmp-antibody-production.htm
The Classification and Naming of Therapeutic Monoclonal Antibodies
Four major mAb types have been developed, murine antibody, chimeric antibody, humanized antibody, and human antibody, according to its increasing content of human sequence.https://www.creativebiolabs.net/engineered-antibodies.htm
Recommended
Approved Therapeutic Antibody Drug and Revenue
The document discusses the four major types of monoclonal antibodies (mAbs) that have been developed: murine, chimeric, humanized, and human. It provides examples of marketed mAb drugs for each type and explains that their generic names follow specific suffixes that indicate the antibody's source and structure. The names generally follow the format of prefix–target–source–suffix according to World Health Organization nomenclature guidelines.
Synteny a million year old euphoria of euphorbiaceae
This document presents the results of a study on synteny between the genome of Ricinus communis and the genomes of several other plants, including Populus trichocarpa, Arabidopsis thaliana, Vitis vinifera, Medicago truncatula, Lotus japonicus, Brachypodium distachyon, Sorghum bicolor, Jatropha curcas, and Manihot esculenta. The study found syntenic relationships between the genome of R. communis and the genomes of these other plants, suggesting conserved chromosomal structures over millions of years of evolution within the plant family Euphorbiaceae.
Ma
This document describes the development of several in vivo experimental models for anti-cancer research including: 1) heterotransplant models using human tumor xenografts in mice to preserve the tumor microenvironment; 2) transgenic mouse models that overexpress oncogenes or knockout tumor suppressor genes; and 3) conditional knockout mouse models where genes can be conditionally deleted in specific tissues. Details are provided on generating transgenic mouse lines that overexpress a deleted form of DNMT3B and generating a conditional HuR knockout mouse line using a targeting vector with loxP sites. The goals are to have repeatable, systematic preclinical models to better evaluate drug efficacy.
Antibody Library Screening - Creative Biolabs
Welcome to Creative Biolabs. As a new preparation technology for genetically engineered antibodies, antibody library technology has important theoretical and practical value in the cloning of human antibodies, antibody performance modification, and antibody gene research. Here, we will explore the de novo antibody library screening technologies and the corresponding services.
Genomic approaches to trypanosome resistance
Elucidating changes in gene expression in Tryp susceptible and resistant cattle during progression of tryp infection using Affymetrix gene expression Micro arrays
B cell sorting
The single plasma cell interrogation platform uses single cell-based screening of entire antibody-secreting B cell populations along with next-generation sequencing to retrieve native antibodies with extremely high in vivo specificity and affinity. During the native antibody development, the isolation and separation of single cells are the main technically challenging tasks. The yield and quality or in other words the integrity and purity of the cells as well as the throughput and the sensitivity of single cell isolation methods should be considered.
Non-GMP Antibody Production
flexible, efficient Non-GMP antibody production services to advance the development of increasing number of therapeutic monoclonal antibody candidates, from process development to aseptic filling
https://www.creativebiolabs.net/non-gmp-antibody-production.htm
The Classification and Naming of Therapeutic Monoclonal Antibodies
Four major mAb types have been developed, murine antibody, chimeric antibody, humanized antibody, and human antibody, according to its increasing content of human sequence.https://www.creativebiolabs.net/engineered-antibodies.htm
ADC conjugate sites analysis
Antibody-drug conjugates employ the specific monoclonal antibodies (mAbs) to achieve targeted delivery of the conjugated cytotoxic molecules to tumor cells.
https://www.creative-biolabs.com/adc/conjugate-sites-analysis.htm
adc chemistry
As one major component of an antibody-drug conjugate (ADC), the antibody is the key for target specificity and serves as the cargo to deliver the cytotoxic drug (payload).
https://www.creative-biolabs.com/adc/antibody-design-and-conjugation.htm
ADC Biotechnology
To retain antibody bioactivity, mild, near-physiological conditions are often used for conjugation reactions. Under these conditions, endogenous amino acids such as Lys and Cys are chemically reactive and can be used as conjugation sites.https://www.creative-biolabs.com/adc/antibody-design-and-conjugation.htm
Antibody Design and Conjugation
As one major component of an antibody-drug conjugate (ADC), the antibody is the key for target specificity and serves as the cargo to deliver the cytotoxic drug (payload). A payload drug can be attached to different sites on an antibody using diverse conjugation chemistry. Multiple endogenous amino acids can serve as potential conjugation sites. However, to achieve more precisely controlled site-directed conjugations and subsequently a narrower distribution of drug-to-antibody ratio (DAR), special moieties with unique conjugation chemistries are engineered into antibody sequences in our antibody design services.
https://www.creative-biolabs.com/adc/antibody-design-and-conjugation.htm
adc cd40
CD40, also known as TNFRSF5, is a type I transmembrane protein. The molecular weight of CD40 is 48-kDa and it consists of a 193 amino acid (aa) extracellular domain, 21 aa leader sequence, 22 aa transmembrane domain, and a 62 aa intracellular domain in human (90 aa in mouse).https://www.creative-biolabs.com/adc/target-cd40-122.htm
ADC Biochemical Analysis
ADC preparation involves the chemical conjugation of the three components and depending on the conjugation strategy used, this process often yields complex and heterogeneous products.https://www.creative-biolabs.com/adc/adc-biochemical-analysis.htm
ADC Antibody Screening
While conventional cancer therapies (surgery, chemo therapy, and radiation therapy) have shown some success in the battle again cancer, they are often accompanied by complex and sometimes, severe side-effects due to the lack of target specificity. To circumvent this flaw and improve the efficacy and safety of cancer treatment, targeted cancer therapies, especially antibody-drug conjugates (ADCs), have been actively exploited and they are gaining a significant amount of attention during the recent years.https://www.creative-biolabs.com/adc/adc-antibody-screening.htm
ADC Affinity Measurement
The elegant design of an antibody-drug conjugate is designated to achieve targeted delivery of the conjugated cytotoxic agents to tumor cells and drug release upon antigen binding and internalization, thus maximizing the antitumor effects while minimizing cytotoxicity to normal tissues. The efficacy of an ADC greatly depends on the specific antigen binding activities of the monoclonal antibody (mAb) portion of the molecule.https://www.creative-biolabs.com/adc/adc-affinity-measurement.htm
5t4 adc
Development of 5T4-based Bispecific ADCs
A bispecific antibody can bind two different targets or two distinct epitopes on the same target. 5T4, specifically overexpressed on the cell surface of various tumors and internalized rapidly when bound to antibody, may be used as an attractive target to develop effective immunotherapy such as bispecific antibody-drug conjugate (ADC).
https://www.creative-biolabs.com/adc/development-of-5t4-based-bispecific-adcs.htm
IND Publishing and Submission
✔ Registration with CTSC
✔ Preparing IND package including Cover letter, IND, 1571, 1572 form and certification form 3674.
✔ Assembling and binding volumes
✔ Submission
https://www.creative-biolabs.com/immuno-oncology/ind-publishing-and-submission.htm
Pre-IND Meeting
For the drug development, pre-IND meeting is a critical tool to discuss the needs and challenges specific to the general product development, nonclinical testing, manufacturing information, protocol design or other regulatory questions defined in the Code of Federal Regulations (21 CFR 312.82). https://www.creative-biolabs.com/immuno-oncology/pre-ind-meeting.htm
Medical Writing and Translation
✔ Clinical overviews (eCTD Module 2.5) including literature review and references
✔ Clinical summaries (eCTD Module 2.7) including clinical pharmacology, efficacy, and safety
✔ Clinical study report preparation and review (eCTD Module 5)
✔ Clinical justification documents for EU, US and other emerging Regulatory markets
✔ Gap analysis for dossiers in clinical module
✔ Clinical and nonclinical document support, handling queries during HA meetings and responding to them
✔ Technical review dossiers
✔ Biowaiver support and justification document services
https://www.creative-biolabs.com/immuno-oncology/medical-writing-and-translation.htm
Regulatory Strategy Consulting
To gain approval for clinical testing after finalizing the pre-clinical testing of innovative new therapies, it is a key milestone for pharmaceutical companies to apply for approval of Investigational New Drug (IND) with FDA or other agencies.https://www.creative-biolabs.com/immuno-oncology/regulatory-strategy-consulting.htm
IND Regulatory Services
Navigating the drug development process from early stage discovery to clinical stage is complex and expensive. https://www.creative-biolabs.com/immuno-oncology/ind-regulatory-services.htm
cGMP Manufacturing
In the United States, the Current Good Manufacturing Practice (cGMP) is the Food and Drug Administration (FDA) 's formal regulations on the design, monitoring, control and maintenance of manufacturing processes and facilities.https://www.creative-biolabs.com/immuno-oncology/cgmp-manufacturing.htm
Antibody and Protein Toxicology
Pre-clinical toxicology is a study of the toxic effects of drugs in development based on statistical and quantitative analysis. https://www.creative-biolabs.com/immuno-oncology/antibody-and-protein-toxicology.htm
Antibody and Protein Pharmacology
Pharmacology is a key component concerned with the study of drug action in animal models which is essential and determinant to IND approval and ultimate NDA approval for a drug candidate. https://www.creative-biolabs.com/immuno-oncology/antibody-and-protein-pharmacology.htm
Role of Mukta Pishti in the Management of Hyperthyroidism
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Cell Therapy Expansion and Challenges in Autoimmune Disease
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
More Related Content
More from EchoHan4
ADC conjugate sites analysis
Antibody-drug conjugates employ the specific monoclonal antibodies (mAbs) to achieve targeted delivery of the conjugated cytotoxic molecules to tumor cells.
https://www.creative-biolabs.com/adc/conjugate-sites-analysis.htm
adc chemistry
As one major component of an antibody-drug conjugate (ADC), the antibody is the key for target specificity and serves as the cargo to deliver the cytotoxic drug (payload).
https://www.creative-biolabs.com/adc/antibody-design-and-conjugation.htm
ADC Biotechnology
To retain antibody bioactivity, mild, near-physiological conditions are often used for conjugation reactions. Under these conditions, endogenous amino acids such as Lys and Cys are chemically reactive and can be used as conjugation sites.https://www.creative-biolabs.com/adc/antibody-design-and-conjugation.htm
Antibody Design and Conjugation
As one major component of an antibody-drug conjugate (ADC), the antibody is the key for target specificity and serves as the cargo to deliver the cytotoxic drug (payload). A payload drug can be attached to different sites on an antibody using diverse conjugation chemistry. Multiple endogenous amino acids can serve as potential conjugation sites. However, to achieve more precisely controlled site-directed conjugations and subsequently a narrower distribution of drug-to-antibody ratio (DAR), special moieties with unique conjugation chemistries are engineered into antibody sequences in our antibody design services.
https://www.creative-biolabs.com/adc/antibody-design-and-conjugation.htm
adc cd40
CD40, also known as TNFRSF5, is a type I transmembrane protein. The molecular weight of CD40 is 48-kDa and it consists of a 193 amino acid (aa) extracellular domain, 21 aa leader sequence, 22 aa transmembrane domain, and a 62 aa intracellular domain in human (90 aa in mouse).https://www.creative-biolabs.com/adc/target-cd40-122.htm
ADC Biochemical Analysis
ADC preparation involves the chemical conjugation of the three components and depending on the conjugation strategy used, this process often yields complex and heterogeneous products.https://www.creative-biolabs.com/adc/adc-biochemical-analysis.htm
ADC Antibody Screening
While conventional cancer therapies (surgery, chemo therapy, and radiation therapy) have shown some success in the battle again cancer, they are often accompanied by complex and sometimes, severe side-effects due to the lack of target specificity. To circumvent this flaw and improve the efficacy and safety of cancer treatment, targeted cancer therapies, especially antibody-drug conjugates (ADCs), have been actively exploited and they are gaining a significant amount of attention during the recent years.https://www.creative-biolabs.com/adc/adc-antibody-screening.htm
ADC Affinity Measurement
The elegant design of an antibody-drug conjugate is designated to achieve targeted delivery of the conjugated cytotoxic agents to tumor cells and drug release upon antigen binding and internalization, thus maximizing the antitumor effects while minimizing cytotoxicity to normal tissues. The efficacy of an ADC greatly depends on the specific antigen binding activities of the monoclonal antibody (mAb) portion of the molecule.https://www.creative-biolabs.com/adc/adc-affinity-measurement.htm
5t4 adc
Development of 5T4-based Bispecific ADCs
A bispecific antibody can bind two different targets or two distinct epitopes on the same target. 5T4, specifically overexpressed on the cell surface of various tumors and internalized rapidly when bound to antibody, may be used as an attractive target to develop effective immunotherapy such as bispecific antibody-drug conjugate (ADC).
https://www.creative-biolabs.com/adc/development-of-5t4-based-bispecific-adcs.htm
IND Publishing and Submission
✔ Registration with CTSC
✔ Preparing IND package including Cover letter, IND, 1571, 1572 form and certification form 3674.
✔ Assembling and binding volumes
✔ Submission
https://www.creative-biolabs.com/immuno-oncology/ind-publishing-and-submission.htm
Pre-IND Meeting
For the drug development, pre-IND meeting is a critical tool to discuss the needs and challenges specific to the general product development, nonclinical testing, manufacturing information, protocol design or other regulatory questions defined in the Code of Federal Regulations (21 CFR 312.82). https://www.creative-biolabs.com/immuno-oncology/pre-ind-meeting.htm
Medical Writing and Translation
✔ Clinical overviews (eCTD Module 2.5) including literature review and references
✔ Clinical summaries (eCTD Module 2.7) including clinical pharmacology, efficacy, and safety
✔ Clinical study report preparation and review (eCTD Module 5)
✔ Clinical justification documents for EU, US and other emerging Regulatory markets
✔ Gap analysis for dossiers in clinical module
✔ Clinical and nonclinical document support, handling queries during HA meetings and responding to them
✔ Technical review dossiers
✔ Biowaiver support and justification document services
https://www.creative-biolabs.com/immuno-oncology/medical-writing-and-translation.htm
Regulatory Strategy Consulting
To gain approval for clinical testing after finalizing the pre-clinical testing of innovative new therapies, it is a key milestone for pharmaceutical companies to apply for approval of Investigational New Drug (IND) with FDA or other agencies.https://www.creative-biolabs.com/immuno-oncology/regulatory-strategy-consulting.htm
IND Regulatory Services
Navigating the drug development process from early stage discovery to clinical stage is complex and expensive. https://www.creative-biolabs.com/immuno-oncology/ind-regulatory-services.htm
cGMP Manufacturing
In the United States, the Current Good Manufacturing Practice (cGMP) is the Food and Drug Administration (FDA) 's formal regulations on the design, monitoring, control and maintenance of manufacturing processes and facilities.https://www.creative-biolabs.com/immuno-oncology/cgmp-manufacturing.htm
Antibody and Protein Toxicology
Pre-clinical toxicology is a study of the toxic effects of drugs in development based on statistical and quantitative analysis. https://www.creative-biolabs.com/immuno-oncology/antibody-and-protein-toxicology.htm
Antibody and Protein Pharmacology
Pharmacology is a key component concerned with the study of drug action in animal models which is essential and determinant to IND approval and ultimate NDA approval for a drug candidate. https://www.creative-biolabs.com/immuno-oncology/antibody-and-protein-pharmacology.htm
More from EchoHan4 (20)
Recently uploaded
Role of Mukta Pishti in the Management of Hyperthyroidism
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Cell Therapy Expansion and Challenges in Autoimmune Disease
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
The Best Ayurvedic Antacid Tablets in India
Treat the symptoms of indigestion, heartburn and stomach reflux with the 10 Best Ayurvedic Antacid Tablets in India.
Adhd Medication Shortage Uk - trinexpharmacy.com
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
NVBDCP.pptx Nation vector borne disease control program
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
A Classical Text Review on Basavarajeeyam
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
ABDOMINAL TRAUMA in pediatrics part one.
Abdominal trauma in pediatrics refers to injuries or damage to the abdominal organs in children. It can occur due to various causes such as falls, motor vehicle accidents, sports-related injuries, and physical abuse. Children are more vulnerable to abdominal trauma due to their unique anatomical and physiological characteristics. Signs and symptoms include abdominal pain, tenderness, distension, vomiting, and signs of shock. Diagnosis involves physical examination, imaging studies, and laboratory tests. Management depends on the severity and may involve conservative treatment or surgical intervention. Prevention is crucial in reducing the incidence of abdominal trauma in children.
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
The Electrocardiogram - Physiologic Principles
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
share - Lions, tigers, AI and health misinformation, oh my!.pptx
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Light House Retreats: Plant Medicine Retreat Europe
Our aim is to organise conscious gatherings and retreats for open and inquisitive minds and souls, with and without the assistance of sacred plants.
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
Recently uploaded (20)
Role of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of Hyperthyroidism
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
Light House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat Europe
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Current naming method of therapeutic mAb drugs
- 1. CREATIVE BIOLABS • RECOMBINANT ANTIBODY 45-1 Ramsey Road, Shirley, NY 11967, USA Email: info@creative-biolabs.com 3 / 20 Table. 2 Current naming method of therapeutic mAb drugs Prefix Target Antibody Source Suffix Some Examples Variable Non- tumor Target Viral -vir- -u- Human mab Pali-vi-zu-mab (humanized antiviral Mab) Bacterial -bac- Immune -lim- -o- Murine Infectious lessions -les- Ada-lim-u-mab (human Mab against immune disease target) Antifungal -fung- -a- Rat Cardiovascular -ci(r)- E-fung-u-mab (human antifungal Mab) Neurologic - ne(r)- -e- Hamster Interleukins -kin- Bapi-neu-zu-mab (humanized Mab against neurobiology target) Musculoskeletal -mul- -i- Primate Bone -os- Uste-kin-u-mab (human anticytokine Mab) Toxin as target -toxa- -xi- Chimeric Tumor Target Colon -col- Den-os-u-mab (human antibone target Mab) Melanoma -mel- -zu- Humaniz ed Mammary -mar- Ab-ci-xi-mab (chimeric Mab against CV target) Testis -got- -axo- Rat/muri ne/hybri d Ovary -gov- Ore-gov-mab (murine Mab for cvarian cancer) Prostate - pr(0)- -xizu- Chimeiri +humani zed Miscellaneous - tu(m) - Adeca-tum-u-mab (human antibody against miscellaneous tumor target)